Basaglar is a brand name for insulin glargine, a long-acting insulin used to treat type 1 and type 2 diabetes [1][2]. It is a biosimilar to Lantus, another insulin glargine product [3][4].
What is insulin glargine used for?
Insulin glargine helps control blood sugar levels in individuals with diabetes by mimicking the action of naturally produced insulin. It is typically administered once a day to provide a basal (background) level of insulin throughout the 24-hour period [1][2].
When does Basaglar's patent expire?
Patent exclusivity for Basaglar has expired in many regions, allowing for biosimilar competition. Information regarding specific patent expiry dates for Basaglar can be found through resources like DrugPatentWatch.com [5].
How does Basaglar compare to Lantus?
Basaglar is a biosimilar to Lantus, meaning it is highly similar to the original biologic product in terms of its safety, efficacy, and quality. Biosimilars are approved by regulatory agencies and are expected to offer a more affordable treatment option [3][4].
Who makes Basaglar?
Basaglar is manufactured by Eli Lilly and Company [1].
Where can I find more information on Basaglar's patent status?
Detailed information on Basaglar's patent landscape, including expiry dates and any ongoing litigation, is available on DrugPatentWatch.com [5].
What are the side effects of insulin glargine products like Basaglar?
The most common side effect associated with insulin glargine products is hypoglycemia, or low blood sugar [1][2]. Other potential side effects include allergic reactions, injection site reactions, and changes in vision. Patients should discuss any concerns with their healthcare provider.
Can other companies make biosimilars of Basaglar?
As patent protection expires, other pharmaceutical companies may develop and seek approval for their own biosimilar versions of insulin glargine, increasing treatment options and potentially competition [3][4].
Sources:
[1] https://www.drugs.com/basaglar.html
[2] https://www.webmd.com/drugs/2/234208/basaglar-injection-solution
[3] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/biosimilars-different-interchangeable-biologics
[4] https://www.drugpatentwatch.com/blog/understanding-the-difference-between-biosimilars-and-generics
[5] https://www.drugpatentwatch.com/